Azoximer Bromide: Mystery, Serendipity, and Promise [PDF]
Azoximer bromide (AZB) was identified as an immunomodulator, and was initially developed and currently successfully indicated as one of several natural polyelectrolytes, a vaccine adjuvant, and an effective agent for the treatment of infectious and ...
Lyudmila Yuryevna Grivtsova +2 more
exaly +4 more sources
Azoximer Bromide and Hydroxyapatite: Promising Immune Adjuvants in Cancer [PDF]
Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations. There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers.
Jean-François Rossi, Patrick Frayssinet
exaly +4 more sources
The Effect of Azoximer Bromide (Polyoxidonium®) in Patients Hospitalized With Coronavirus Disease (COVID-19): An Open-Label, Multicentre, Interventional Clinical Study. [PDF]
A clinical need for aetiotropic coronavirus disease (COVID-19) treatments is required. The immune modulator azoximer bromide (AZB; Polyoxidonium®) is indicated in Russia for use against acute viral infections and during remission.
Natallia V Matsiyeuskaya +2 more
exaly +4 more sources
Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study [PDF]
The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open ...
Sergey V Efimov +10 more
doaj +2 more sources
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. [version 2; peer review: 2 approved] [PDF]
A systematic review of clinical trials conducted with a low-dose inactivated influenza vaccine adjuvanted by azoximer bromide (AZB, Polyoxidonium), was performed to compare vaccine reactogenicity against non-adjuvant vaccines.
Susanna Kharit +6 more
doaj +2 more sources
Use of immunomodulatory therapy as part of comprehensive treatment of non-severe community-acquired pneumonia and its long-term results [PDF]
Background: This study investigates the efficiency of two different types of immunomodulators for the treatment of non-severe community-acquired pneumonia (CAP) and assesses their long-term effects.
Mikhail P Kostinov +5 more
doaj +2 more sources
Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination [PDF]
Background: for the first time, the effect of one and two doses of adjuvanted influenza vaccines on toll-like receptors (TLRs) in patients with common variable immunodeficiency (CVID) was studied and compared (primary vaccination with one vs.
Aristitsa Mikhailovna Kostinova +9 more
doaj +2 more sources
Relevance. Despite the implementation of measures to reduce morbidity and mortality among medical workers who are in contact with patients hospitalized for a new coronavirus infection caused by SARS-CoV-2 (hereinafter – COVID-19), their level remains ...
A E Zobov, K V Zhdanov, A A Kuzin
exaly +3 more sources
Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency [PDF]
Background: Recent addition to vaccines of adjuvants has been actively used to enhance the immunogenicity. However, the use of adjuvants for the development of quadrivalent inactivated influenza vaccines (QIV) is currently limited.
Aristitsa Mikhailovna Kostinova +8 more
doaj +2 more sources
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19 [PDF]
Background: Evidence-based therapies used to treat coronavirus disease (COVID-19) remain limited. Azoximer bromide (AZB; Polyoxidonium®) is an immunomodulating molecule frequently used in the Russian Federation. It offers demonstrable therapeutic benefit
Sergey V Efimov +11 more
doaj +2 more sources

